ES2001019A6 - Procedimiento para preparar hidroxialquilxantinas terciarias - Google Patents

Procedimiento para preparar hidroxialquilxantinas terciarias

Info

Publication number
ES2001019A6
ES2001019A6 ES8600356A ES8600356A ES2001019A6 ES 2001019 A6 ES2001019 A6 ES 2001019A6 ES 8600356 A ES8600356 A ES 8600356A ES 8600356 A ES8600356 A ES 8600356A ES 2001019 A6 ES2001019 A6 ES 2001019A6
Authority
ES
Spain
Prior art keywords
pct
carbon atoms
tertiary
sec
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8600356A
Other languages
English (en)
Inventor
Ulrich Gebert
Ismahan Okyayuz-Baklouti
Werner Thorwart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES2001019A6 publication Critical patent/ES2001019A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL PROCEDIMIENTO DESCRITO PREPARA COMPUESTOS DE FORMULA I DONDE AL MENOS UNO DE LOS RADICALES R1 Y R3 REPRESENTA UN GRUPO HIDROXIALQUILO TERCIARIO Y EL OTRO DE ESOS RADICALES, EVENTUALMENTE EXISTENTE, REPRESENTA HIDROGENO O UN RADICAL HIDROCARBONADO ALIFATICO, Y R2 REPRESENTA UN GRUPO ALQUILO DE 1 A 4 ATOMOS DE CARBONO, HACIENDO REACCIONAR 3-ALQUILXANTINAS DE FORMULA DONDE R2 ES COMO SE HA DEFINIDO ANTES, CON AGENTES ALQUILANTES DE FORMULA DONDE X ES HALOGENO O UNA AGRUPACION ESTER DE ACIDO SULFONICO O DE ACIDO FOSFORICO, R4 ES ALQUILO DE HASTA 3 ATOMOS DE CARBONO Y N ES 2 A 5. LOS COMPUESTOS DE FORMULA I SE PUEDEN PREPARAR TAMBIEN SIGUIENDO VIAS ALTERNATIVAS EXPLICADAS EN LA MEMORIA. ESTOS COMPUESTOS SON ESPECIALMENTE ADECUADOS PARA TRATAR ALTERACIONES DE LA CIRCULACION SANGUINEA PERIFERICA Y CEREBRAL.
ES8600356A 1985-07-19 1986-07-17 Procedimiento para preparar hidroxialquilxantinas terciarias Expired ES2001019A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853525801 DE3525801A1 (de) 1985-07-19 1985-07-19 Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung

Publications (1)

Publication Number Publication Date
ES2001019A6 true ES2001019A6 (es) 1988-04-16

Family

ID=6276182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600356A Expired ES2001019A6 (es) 1985-07-19 1986-07-17 Procedimiento para preparar hidroxialquilxantinas terciarias

Country Status (33)

Country Link
US (1) US4833146A (es)
EP (1) EP0268585B1 (es)
JP (1) JPH0788382B2 (es)
KR (1) KR950001019B1 (es)
CN (1) CN1026112C (es)
AR (1) AR244689A1 (es)
AT (1) ATE53211T1 (es)
AU (1) AU588350B2 (es)
BG (1) BG60767B2 (es)
CA (1) CA1262248A (es)
CS (1) CS272766B2 (es)
DD (1) DD261156A5 (es)
DE (2) DE3525801A1 (es)
DK (1) DK157867C (es)
ES (1) ES2001019A6 (es)
FI (1) FI89921C (es)
GR (1) GR861866B (es)
HU (1) HU198486B (es)
IE (1) IE59025B1 (es)
IL (1) IL79457A0 (es)
LT (1) LT3869B (es)
LV (1) LV5703A3 (es)
MA (1) MA20739A1 (es)
MX (1) MX9254A (es)
NO (1) NO165803C (es)
NZ (1) NZ216888A (es)
OA (1) OA08707A (es)
PH (1) PH26262A (es)
PT (1) PT83013B (es)
RU (1) RU2051918C1 (es)
TN (1) TNSN86111A1 (es)
WO (1) WO1987000523A2 (es)
ZA (1) ZA865374B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
IT1240843B (it) * 1990-05-24 1993-12-17 Malesci Istituto Farmacobiologico Derivati xantinici 1-7 sostituiti ad attivita' antiasmatica, loro sali fisiologicamente accettabili, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
DK0484785T3 (da) * 1990-11-07 1996-09-23 Hoechst Marion Roussel Inc Anvendelse af xanthiner til fremstilling af et lægemiddel, der er virksomt til inhibering af formeringen af humane retrovira
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (es) * 1991-12-11 1993-07-21 Hoechst Ag
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
DK0584347T3 (da) * 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomere hydroxylerede xanthinforbindelser
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
WO1995022546A1 (en) * 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
DE10042152A1 (de) * 2000-08-26 2002-03-28 Basf Coatings Ag Mit aktinischer Strahlung aktivierbares Thixotropierungsmittel, Verfahren zu seiner Herstellung und seine Verwendung
DE10122390A1 (de) * 2001-05-09 2002-11-28 Basf Coatings Ag Carbamat-und/oder Allophanatgruppen enthaltende, thermisch härtbare, thixotrope Gemische
DE10139262C1 (de) * 2001-08-09 2003-01-02 Basf Coatings Ag Rheologiehilfsmittel, Verfahren zu seiner Herstellung und seine Verwendung
AU2002304685A1 (en) * 2002-04-24 2003-11-10 Basf Coatings Ag Thermally curable, thixotropic mixtures containing carbamate and/or allophanate groups
KR100872788B1 (ko) * 2002-05-28 2008-12-09 엘지전자 주식회사 드럼세탁기
US8686090B2 (en) * 2003-12-10 2014-04-01 Basf Coatings Gmbh Use of urea crystals for non-polymeric coatings
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
WO2009108383A2 (en) * 2008-02-29 2009-09-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
JP2011516464A (ja) * 2008-03-31 2011-05-26 サン・ファーマシューティカル・インダストリーズ・リミテッド モルフィナン類似体の改良された調製方法
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
MX2012002704A (es) 2009-09-02 2012-03-21 Concert Pharmaceuticals Inc Derivados de xantina sustituidos.
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
MX2014012384A (es) 2012-04-13 2014-11-26 Concert Pharmaceuticals Inc Derivados sustituidos de xantina.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
BE795345A (fr) * 1972-02-19 1973-08-13 Albert Ag Chem Werke MEDICAMENT UTILE NOTAMMENT POUR L'IRRIGATION CEREBRALE, PROCEDE DE PREPARATION DE SES MATIERES ACTIVES ET CES MATIERES ElLES-MEMES
CH622519A5 (en) * 1974-07-05 1981-04-15 Hoechst Ag Process for the preparation of hydroxyalkylxanthines
DE2432702C2 (de) * 1974-07-08 1983-01-20 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Hydroxyalkylxanthinen
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
EP0017478B1 (en) * 1979-04-05 1983-03-30 BEECHAM - WUELFING GmbH & Co. KG Dialkoxy- and dioxacycloalkyl-alkyltheobromines, pharmaceutical compositions containing them and their preparation
JPS5838284A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4575795A (en) * 1983-04-01 1986-03-11 Honeywell Information Systems Inc. Apparatus for detecting a predetermined character of a data string

Also Published As

Publication number Publication date
MA20739A1 (fr) 1987-04-01
IE59025B1 (en) 1993-12-15
JPS63501149A (ja) 1988-04-28
AR244689A1 (es) 1993-11-30
LT3869B (en) 1996-04-25
US4833146A (en) 1989-05-23
CN1026112C (zh) 1994-10-05
DK157867B (da) 1990-02-26
NO165803C (no) 1991-04-10
DK139287D0 (da) 1987-03-18
ATE53211T1 (de) 1990-06-15
WO1987000523A3 (fr) 1987-02-26
DK157867C (da) 1990-07-30
MX9254A (es) 1993-06-01
DK139287A (da) 1987-03-18
PT83013A (de) 1986-08-01
GR861866B (en) 1986-11-17
KR950001019B1 (ko) 1995-02-07
EP0268585B1 (de) 1990-05-30
FI880174A (fi) 1988-01-15
CA1262248A (en) 1989-10-10
KR870700623A (ko) 1987-12-30
LV5703A3 (lv) 1995-02-20
NO871111L (no) 1987-03-18
HUT47274A (en) 1989-02-28
CS272766B2 (en) 1991-02-12
FI89921B (fi) 1993-08-31
PT83013B (pt) 1989-01-30
FI89921C (fi) 1993-12-10
IE861917L (en) 1987-01-19
NO871111D0 (no) 1987-03-18
PH26262A (en) 1992-04-01
BG60767B2 (bg) 1996-02-29
NO165803B (no) 1991-01-02
CN86105835A (zh) 1987-01-14
AU6143986A (en) 1987-02-10
HU198486B (en) 1989-10-30
OA08707A (en) 1989-03-31
EP0268585A1 (de) 1988-06-01
LTIP1467A (en) 1995-05-25
DE3671627D1 (de) 1990-07-05
NZ216888A (en) 1989-05-29
JPH0788382B2 (ja) 1995-09-27
TNSN86111A1 (fr) 1990-01-01
DE3525801A1 (de) 1987-01-22
ZA865374B (en) 1987-02-25
IL79457A0 (en) 1986-10-31
DD261156A5 (de) 1988-10-19
CS545386A2 (en) 1990-04-11
RU2051918C1 (ru) 1996-01-10
WO1987000523A2 (en) 1987-01-29
AU588350B2 (en) 1989-09-14
FI880174A0 (fi) 1988-01-15

Similar Documents

Publication Publication Date Title
ES2001019A6 (es) Procedimiento para preparar hidroxialquilxantinas terciarias
ES8305356A1 (es) Un procedimiento para la produccion de un derivado de carbostirilo
IL65501A (en) 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
FR2603037A1 (fr) (pentamethyl-1,2,2,6,6,6 piperidyl-4 amino)- triazines, leur application comme stabilisants de matieres organiques, et compositions qui en contiennent
DE3170504D1 (en) Piperidylidene derivatives, their production and pharmaceutical compositions containing them
EP0482071A4 (en) New antiviral agents
MY104335A (en) 4-aminophridine deravatives
ES8305736A1 (es) Procedimiento para la preparacion de derivados de la piridazina.
DE3264172D1 (en) N-2-hydroxypropyl piperidines and process for preparing the same
ES8401068A1 (es) Procedimiento para la preparacion de derivados de corinanteina, asi como de sus sales de adicion acida fisiologicamente inocuas.
ZA835390B (en) 7-acylthio-15,16-methylene-3-oxo-17-pregna-1,4-diene 21,17-carbolactones,their preparation and use as medicinal agents
ES475587A1 (es) Procedimiento para preparar derivados de isoquinolina
HU9300476D0 (en) Method for producing pharmaceutical preparatives containing xanthine derivatives
ES8301919A1 (es) Procedimiento para preparar derivados de indano
ES8401059A1 (es) Procedimiento para la preparacion de fenoleteres biciclicos.
ES8607971A1 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-tio-alquilo inferior-penem
EP0196330A1 (de) Verwendung von pyrrothinderivaten.
GR3000773T3 (en) 2,2;6,6-diethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactones, process for their preparation and pharmaceutical compositions containing them
JPS57108087A (en) (4,5)-4h-benzo(1,2-b)cycloheptafuran derivative, manufacture and use as medicine
EP0062068A4 (en) N-PHTHALIDYL-5-FLUOROURACILE DERIVATIVES.
ES478072A1 (es) Un procedimiento de preparacion de 2-metoxi-benzamidas.
UA41309C2 (uk) ПОХІДНІ 11-<font face="Symbol">b</font>-БЕНЗАЛЬДОКСИМЕСТРА-4,9-ДІЄНУ, СПОСІБ ЇХ ОТРИМАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
TH2173B (th) สารประกอบไทรไซคลิค
ZA839434B (en) A process for preparing oxanosine and an intermediate used in this process
TH919EX (th) การเตรียมอนุพันธ์ 1-แอลคิล-2-อะมิโน-เททราลิน